Short answer: For clinics in Kuala Lumpur and the Klang Valley, referring a patient to a compounding pharmacy means sending a named-patient prescription to a non-sterile compounding pharmacy that prepares the formulation under Good Compounding Practice (GCP). Lynnity Pharma, based in Kuala Lumpur, operates on this prescription-only model — every preparation is made for one individual on a doctor’s prescription.A The practical referral steps are straightforward: write the prescription, include a formulation brief, and confirm the dosage form and excipient requirements with the pharmacy. This guide walks through each step and addresses the questions clinics most often ask when referring for the first time.
How to refer a patient to a KL compounding pharmacy
The referral process is simpler than many clinics expect. It does not require a directory lookup or a separate authorization — it requires a prescription and a formulation brief. The pharmacy prepares the formulation on the prescriber’s order, for one named patient, within the scope of non-sterile compounding.
Step 1: Write the prescription
The prescription should name the patient, specify the active ingredient and strength, and state the requested dosage form (capsule, liquid, cream, tonic or serum). If the prescriber has a specific vehicle or excipient preference, this should be noted. The prescription is the legal and clinical basis for the preparation — no compounded preparation is made without one.A
For prescribers new to compounding referrals, the most common gap is omitting the dosage form. A prescription that names the active and strength but does not state whether a capsule, liquid or cream is needed leaves the pharmacy to guess, which can delay preparation. If the prescriber is unsure which form is most appropriate, this can be flagged as a question for the pharmacy rather than left blank.
Step 2: Include a formulation brief
Beyond the prescription itself, a concise formulation brief helps the pharmacy assess practicality. Useful details include the clinical rationale, the anatomical site (for topical preparations), any known excipient exclusions or sensitivities, previous product tolerability issues, and the prescriber’s review plan. This is a collaborative step — the pharmacy may advise on compatibility or stability before finalising the formulation.B
The formulation brief does not need to be lengthy. A few sentences covering why compounding is being considered, what has been tried before, and what the prescriber wants to achieve is usually sufficient. The pharmacy uses this information to assess whether the requested preparation is practical and to flag any compatibility or stability concerns before proceeding.
Step 3: Confirm dosage form and excipient requirements
Non-sterile compounding covers five dosage forms: capsules, liquids, creams, tonics and serums. The pharmacy should confirm which form is appropriate for the clinical brief and flag any excipient that is unsuitable for the patient. For preparations involving liposomal delivery, quality and stability questions should be discussed before finalising.C
Excipient requirements are particularly relevant for patients with known sensitivities. If a patient has reacted to a preservative, fragrance or other non-active component in a commercial product, noting this in the formulation brief allows the pharmacy to consider a simpler formulation that excludes the problematic ingredient. This does not guarantee that irritation will not occur, but it can reduce avoidable formulation complexity.
What information helps the pharmacy prepare an accurate formulation
The more specific the referral, the fewer back-and-forth queries are needed before preparation can begin. The most useful information typically includes:
- The patient’s name and the prescriber’s details
- The active ingredient, strength and requested dosage form
- The clinical rationale for compounding (e.g. intolerance to a commercial product, need for a specific vehicle, regimen simplification)
- The anatomical site for topical preparations
- Known excipient exclusions or sensitivities
- Previous product tolerability issues
- The intended directions for use and review plan
When this information is provided upfront, the pharmacy can assess the formulation, confirm compatibility and stability, and prepare the product without unnecessary delays. Missing information does not block the referral, but it may extend the time to preparation if the pharmacy needs to contact the clinic for clarification.
What to expect from the pharmacy
The compounding pharmacy should acknowledge the prescription, confirm the formulation details, and prepare the product with a beyond-use date that reflects the preparation’s stability. The preparation is made to order for one patient — it is not a mass-produced product with a factory expiry date. Clinic staff should ensure the patient understands the beyond-use date and usage instructions.D
The pharmacy may also provide counselling information, including how to store the preparation, how often to apply or take it, and what to do if the patient experiences any issues. This information supports the prescriber’s review plan and helps the patient use the preparation correctly between clinic visits.
When to contact the pharmacy before referring
If the formulation is unusual — a specific combination, a liposomal delivery form, or a preparation with complex stability requirements — it is sensible to contact the pharmacy before sending the prescription. This allows the pharmacy to assess whether the requested preparation is practical within non-sterile compounding scope and to flag any issues early.
Pre-referral contact is also useful when the prescriber is uncertain about the most appropriate dosage form, or when the patient has multiple excipient sensitivities that may limit formulation options. In these cases, a brief discussion with the pharmacy can help the prescriber refine the formulation brief before the formal prescription is written.
Common referral scenarios in KL and Klang Valley practice
Clinics in the Klang Valley refer for a range of practical reasons. Common scenarios include:
- A patient who cannot tolerate a commercial product due to specific excipients and needs a simpler formulation
- A prescriber who wants a specific active ingredient in a vehicle better suited to the anatomical site or patient preference
- A patient whose regimen involves multiple products and would benefit from a simplified approach
- A prescriber who wants to explore liposomal delivery for a specific nutrient where the evidence supports consideration
In each case, the referral is a formulation decision driven by the prescriber’s clinical judgement, not a substitute for evidence-based care. The pharmacy’s role is to prepare the formulation to specification and advise on compatibility, stability and quality within non-sterile compounding scope.
How this fits the Lynnity practice context
Lynnity Pharma is a non-sterile compounding pharmacy based in Kuala Lumpur, serving the Klang Valley with practitioner referrals and enquiries also coming from Singapore. The service operates on a prescription-only, named-patient basis under Good Compounding Practice, covering capsules, liquids, creams, tonics and serums.AC For clinics referring to Lynnity, the process is the same as described above: write the prescription, include a formulation brief, and confirm the dosage form and excipient requirements. The pharmacy can be contacted to discuss formulation feasibility before the prescription is finalised.
Frequently asked questions
How does a clinic in KL refer a patient to a compounding pharmacy?
Write a named-patient prescription specifying the active, strength and dosage form, include a formulation brief with excipient requirements and the review plan, and send it to the pharmacy. The pharmacy confirms the formulation and prepares it under Good Compounding Practice.A
Does the patient need to visit the pharmacy in person?
That depends on the pharmacy’s processes and the clinic’s arrangement. The key requirement is the prescription — the pharmacy prepares the formulation on the prescriber’s order. Clinic staff should confirm the preferred communication channel with the pharmacy.
What dosage forms can a non-sterile compounding pharmacy prepare?
Non-sterile compounding covers capsules, liquids, creams, tonics and serums. Sterile preparations such as injectables or ophthalmic products are outside this scope. The pharmacy should confirm which form suits the clinical brief.C
What should a prescriber do if unsure about the most appropriate dosage form?
Contact the pharmacy before writing the prescription. The pharmacy can advise on which non-sterile dosage form is practical for the requested active and clinical brief, and flag any compatibility or stability considerations. This is a collaborative discussion, not an administrative step.
How does the beyond-use date affect the review plan?
Compounded preparations carry a beyond-use date rather than a factory expiry date. The review plan should align with this stability window, so the prescriber knows when to assess response and whether repeat supply is needed before the preparation’s beyond-use date expires.D
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
For practitioner enquiries, clinicians can discuss referral steps and patient-specific formulation needs with the Lynnity team.
Grounding source A: Lynnity Pharma blog post ID 374663, https://www.lynnitypharma.com/blog/compounded-pregnenolone-malaysia/
Grounding source B: Lynnity Pharma blog post ID 374640, https://www.lynnitypharma.com/blog/compounded-citicoline-cdp-choline-malaysia/
Grounding source C: Lynnity Pharma blog post ID 374539, https://www.lynnitypharma.com/blog/compounded-liposomal-nac-n-acetylcysteine-malaysia/
Grounding source D: Lynnity Pharma blog post ID 374505, https://www.lynnitypharma.com/blog/beyond-use-dating-compounded-supplements-malaysia/